Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Kite Pharma
Sort By
Newest First
1 / 1
Capacity Expansion
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
Gilead Sciences
PR-M07-19-NI-043
Jul 17, 2019
Drug Development
Kite Makes Move on Gadeta
Nice Insight
PAO-M07-18-NI-019
Jul 24, 2018
Oncology
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Sangamo Therapeutics
PR-M02-18-NI-95
Feb 26, 2018
Acquisition
Gilead’s new Kite Subsidiary To Buy CAR-T Cell Therapy Company Cell Design Labs
Nice Insight
PAO-M01-18-NI-001
Jan 02, 2018
Drug Development
ZUMA-1 Study of Yescarta Reports 58% Complete Remission
Nice Insight
PAO-M12-17-NI-016
Dec 12, 2017
Drug Development
U.S. Patient Receives Kite’s Yescarta CART-T Therapy
Nice Insight
PAO-M12-17-NI-008
Dec 07, 2017
CAR-T
Breakthrough CAR-T Immunotherapy Approved
Nice Insight
PAO-M10-17-NI-037
Oct 26, 2017
Acquistion
Kite Pharma Acquisition by Gilead Finalized
Nice Insight
PAO-M10-17-NI-017
Oct 13, 2017
Acquisition
Gilead Sciences to Fly Kite Pharma for $11.9 Billion
Nice Insight
PAO-M08-17-NI-036
Aug 29, 2017
NDA
Kite Submits Investigational New Drug Application for KITE-585
Emilie Branch
Pharma's Almanac
PAO-M08-17-NI-018
Aug 11, 2017
Clinical Trials
Priority Review Given to Kite’s Axicabtagene Ciloleucel
Nice Insight
PAO-M05-17-NI-034
May 31, 2017
1 / 1
